Volume | 1,863,557 |
|
|||||
News | - | ||||||
Day High | 8.45 | Low High |
|||||
Day Low | 8.10 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Ironwood Pharmaceuticals Inc | IRWD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
8.45 | 8.10 | 8.45 | 8.12 | 8.30 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
15,877 | 1,863,557 | $ 8.21 | $ 15,298,223 | - | 7.53 - 15.70 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:20:28 | formt | 100 | $ 8.1002 | USD |
Ironwood Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.27B | 156.53M | - | 442.74M | -1B | -6.40 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Ironwood Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IRWD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 8.09 | 8.45 | 7.69 | 7.97 | 2,744,703 | 0.0102 | 0.13% |
1 Month | 8.18 | 8.45 | 7.53 | 7.95 | 2,544,211 | -0.0798 | -0.98% |
3 Months | 14.86 | 15.70 | 7.53 | 9.75 | 4,690,719 | -6.76 | -45.49% |
6 Months | 9.11 | 15.70 | 7.53 | 10.55 | 3,599,535 | -1.01 | -11.08% |
1 Year | 10.50 | 15.70 | 7.53 | 10.29 | 2,956,849 | -2.40 | -22.86% |
3 Years | 11.08 | 15.70 | 7.53 | 11.11 | 2,505,642 | -2.98 | -26.89% |
5 Years | 10.17 | 15.70 | 7.53 | 10.92 | 2,225,928 | -2.07 | -20.35% |
Ironwood Pharmaceuticals Description
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. |